These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 31750274)

  • 21. A novel oncolytic adenovirus based on simian adenovirus serotype 24.
    Cheng T; Song Y; Zhang Y; Zhang C; Yin J; Chi Y; Zhou D
    Oncotarget; 2017 Apr; 8(16):26871-26885. PubMed ID: 28460470
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncolytic adenoviruses: A thorny path to glioma cure.
    Ulasov IV; Borovjagin AV; Schroeder BA; Baryshnikov AY
    Genes Dis; 2014 Dec; 1(2):214-226. PubMed ID: 25685829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma.
    Sonabend AM; Ulasov IV; Tyler MA; Rivera AA; Mathis JM; Lesniak MS
    Stem Cells; 2008 Mar; 26(3):831-41. PubMed ID: 18192232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
    Wohlfahrt ME; Beard BC; Lieber A; Kiem HP
    Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical safety assessment of Ad[I/PPT-E1A], a novel oncolytic adenovirus for prostate cancer.
    Schenk E; Essand M; Kraaij R; Adamson R; Maitland NJ; Bangma CH
    Hum Gene Ther Clin Dev; 2014 Mar; 25(1):7-15. PubMed ID: 24649837
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of immunotherapy for high-grade gliomas: Overcoming the immunosuppressive tumor microenvironment.
    Franson A; McClellan BL; Varela ML; Comba A; Syed MF; Banerjee K; Zhu Z; Gonzalez N; Candolfi M; Lowenstein P; Castro MG
    Front Med (Lausanne); 2022; 9():966458. PubMed ID: 36186781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Advances in oncolytic virotherapy for glioma].
    Zhu GL; Wu S; Wu JS
    Zhonghua Wai Ke Za Zhi; 2023 Dec; 62(1):78-83. PubMed ID: 38044611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prime-boost immunization by both DNA vaccine and oncolytic adenovirus expressing GM-CSF and shRNA of TGF-β2 induces anti-tumor immune activation.
    Kim SY; Kang D; Choi HJ; Joo Y; Kim JH; Song JJ
    Oncotarget; 2017 Feb; 8(9):15858-15877. PubMed ID: 28178658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. GITRL-armed Delta-24-RGD oncolytic adenovirus prolongs survival and induces anti-glioma immune memory.
    Rivera-Molina Y; Jiang H; Fueyo J; Nguyen T; Shin DH; Youssef G; Fan X; Gumin J; Alonso MM; Phadnis S; Lang FF; Gomez-Manzano C
    Neurooncol Adv; 2019; 1(1):vdz009. PubMed ID: 31608328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment.
    van den Bossche WBL; Kleijn A; Teunissen CE; Voerman JSA; Teodosio C; Noske DP; van Dongen JJM; Dirven CMF; Lamfers MLM
    Neuro Oncol; 2018 Oct; 20(11):1494-1504. PubMed ID: 29796615
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives.
    Taguchi S; Fukuhara H; Todo T
    Jpn J Clin Oncol; 2019 Mar; 49(3):201-209. PubMed ID: 30462296
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma.
    Ulasov IV; Zhu ZB; Tyler MA; Han Y; Rivera AA; Khramtsov A; Curiel DT; Lesniak MS
    Hum Gene Ther; 2007 Jul; 18(7):589-602. PubMed ID: 17630837
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
    Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL
    Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity.
    Angelova AL; Barf M; Geletneky K; Unterberg A; Rommelaere J
    Viruses; 2017 Dec; 9(12):. PubMed ID: 29244745
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hitting the nail on the head: combining oncolytic adenovirus-mediated virotherapy and immunomodulation for the treatment of glioma.
    Panek WK; Kane JR; Young JS; Rashidi A; Kim JW; Kanojia D; Lesniak MS
    Oncotarget; 2017 Oct; 8(51):89391-89405. PubMed ID: 29179527
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deficiency of the IRE1α-Autophagy Axis Enhances the Antitumor Effects of the Oncolytic Virus M1.
    Li K; Hu C; Xing F; Gao M; Liang J; Xiao X; Cai J; Tan Y; Hu J; Zhu W; Yin W; Li Y; Chen W; Lu B; Mai J; Qiu P; Su X; Yan G; Zhang H; Lin Y
    J Virol; 2018 Mar; 92(6):. PubMed ID: 29263275
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune Suppression during Oncolytic Virotherapy for High-Grade Glioma; Yes or No?
    Koks CA; De Vleeschouwer S; Graf N; Van Gool SW
    J Cancer; 2015; 6(3):203-17. PubMed ID: 25663937
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oncolytic viruses for treatment of malignant brain tumours.
    Rainov NG; Ren H
    Acta Neurochir Suppl; 2003; 88():113-23. PubMed ID: 14531569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment.
    Meisen WH; Wohleb ES; Jaime-Ramirez AC; Bolyard C; Yoo JY; Russell L; Hardcastle J; Dubin S; Muili K; Yu J; Caligiuri M; Godbout J; Kaur B
    Clin Cancer Res; 2015 Jul; 21(14):3274-85. PubMed ID: 25829396
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Irradiation enhances the therapeutic effect of the oncolytic adenovirus XVir-N-31 in brain tumor initiating cells.
    Czolk R; Schwarz N; Koch H; Schötterl S; Wuttke TV; Holm PS; Huber SM; Naumann U
    Int J Mol Med; 2019 Oct; 44(4):1484-1494. PubMed ID: 31432139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.